True BUT many of these become more of a play as date gets closer (like Er plays) so keeping on watch.
@fireopal - exactly - they'll keep running it up - and probably sell on good news or bad - thx for the heads-up!
it's like new internet start-ups: 1999 - 2002; most of these baby bios will run out of $$ within 2 years - however, a few will be bought by the majors and a very, very small few will become an Amgen, Biogen, etc. High risk spec for long term imo.
Watching YRD - VERI for another entry since $39's are gone & couple under $10 along with whatever else pops in the morning so the readers will have to check back in the morning
YRD? That's one I've been playing...very tricky rabbitt....can move $3 -$5 range easily in a day - waiting for a retrace to 35ish.
Wed. 10/4: GELYF: $3.43 +7% (52 wk. high) & MYL: $38.13 +17% - been banging the drum on MYL for 2 months since hedge funds bought in.
crazy pre >> MTBC the from outa nowhere play today that actually started yesterday - MTBC Signs New talkEHR Customers in 42 States During First Month of Rollout - https://finance.yahoo.com/news/mtbc-signs-talkehr-customers-42-110000066.html @Neil Allen posted this news in MYL thread last night - Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity - https://finance.yahoo.com/news/mylan-announces-u-fda-approval-000800014.html
BLRX: $1.20 - "According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “ Several other research analysts have also recently weighed in on the company. Maxim Group set a $3.00 target price on BioLineRx and gave the company a “buy” rating in a research note on Monday, July 10th. HC Wainwright set a $4.00 price target on shares of BioLineRx and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Roth Capital set a $3.00 price target on shares of BioLineRx and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $3.00 price target on shares of BioLineRx in a research report on Tuesday, September 12th.
ROKU nice reversal - VERI falling off a cliff lol - SGBX (IPO) was looking forward to this one & really liked the concept but did not do well at all but yesterday news had it moving up & up more today >> SG Blocks Secures Two Low Income Housing Development Projects In New York State Representing Largest Project Awards in Company History. https://finance.yahoo.com/news/sg-blocks-secures-two-low-123100757.html
ITCI: $16.70 (biotech) being accumulated with large insider buys; $28 target by analysts. "Analysts on a consensus basis are expecting that the stock will reach $28 within the year." Intra-Cellular Therapies - focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). 2017-10-02 Alafi Christopher D (Director) Buy 258,065 15.50 4,000,007 2017-10-02 Alafi Capital Co Llc (10% Owner) Buy 258,065 15.50 4,000,007 2017-10-02 Alafi Moshe (10% Owner) Buy 258,065 15.50 4,000,007
under a dollar? how 'bout under a penny OTTV: .0019 - incredibly - it's a real company with internet app for cable TV subscriptions.
Thanks for bringing this one up. Adding >> your chart isn't showing the nice gap to $40 ranges so definitely watching this one Intra-Cellular Therapies Announces Commencement of Enrollment of a Clinical Trial Evaluating ITI-214 in Patients with Parkinson’s Disease -https://finance.yahoo.com/news/intra-cellular-therapies-announces-commencement-120000654.html Intra-Cellular Therapies Announces Closing of $150 Million Public Offering of Common Stock - https://finance.yahoo.com/news/intra-cellular-therapies-announces-closing-200100720.html
Had a feeling - was up a bit too much yesterday but didn't do b/c realized that it was not going to be a fast short & don't want to hold. LULU went down a bit too but looks like it is fighting going down lol
